PMA
VRTX icon

Prudent Man Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Prudent Man Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.9M Buy
3,827
+400
+12% +$177K 0.43% 61
2026
Q1 		$1.53M Buy
3,427
+1,298
+61% +$605K 0.46% 56
2025
Q4 		$965K Buy
2,129
+578
+37% +$249K 0.35% 61
2025
Q3 		$607K Sell
1,551
-184
-11% -$76.9K 0.22% 88
2025
Q2 		$772K Buy
1,735
+376
+28% +$173K 0.25% 93
2025
Q1 		$659K Sell
1,359
-403
-23% -$188K 0.24% 100
2024
Q4 		$710K Sell
1,762
-122
-6% -$56.6K 0.26% 84
2024
Q3 		$876K Sell
1,884
-124
-6% -$59.6K 0.29% 85
2024
Q2 		$941K Buy
2,008
+74
+4% +$32.1K 0.33% 69
2024
Q1 		$808K Sell
1,934
-123
-6% -$52K 0.3% 79
2023
Q4 		$837K Sell
2,057
-30
-1% -$11.1K 0.31% 71
2023
Q3 		$726K Sell
2,087
-71
-3% -$24.8K 0.29% 79
2023
Q2 		$759K Sell
2,158
-30
-1% -$10.1K 0.29% 74
2023
Q1 		$689K Sell
2,188
-25
-1% -$7.5K 0.27% 84
2022
Q4 		$639K Buy
2,213
+588
+36% +$179K 0.26% 98
2022
Q3 		$471K Sell
1,625
-12
-0.7% -$3.45K 0.22% 95
2022
Q2 		$461K Sell
1,637
-28
-2% -$7.49K 0.22% 95
2022
Q1 		$435K Sell
1,665
-59
-3% -$14K 0.18% 105
2021
Q4 		$379K Sell
1,724
-3
-0.2% -$583 0.14% 114
2021
Q3 		$313K Sell
1,727
-21
-1% -$4.1K 0.12% 136
2021
Q2 		$352K Buy
1,748
+53
+3% +$11.1K 0.14% 122
2021
Q1 		$364K Buy
1,695
+83
+5% +$18.2K 0.15% 116
2020
Q4 		$381K Sell
1,612
-31
-2% -$7.11K 0.16% 110
2020
Q3 		$447K Buy
1,643
+54
+3% +$14.9K 0.24% 87
2020
Q2 		$461K Buy
+1,589
New +$431K 0.41% 70

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Prudent Man Advisors's VRTX Position: Q2 2026 in Review

Prudent Man Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $177K and bringing the position to 3,827 shares worth $1.9M. The position accounts for 0.43% of the portfolio, ranked #61.

Prudent Man Advisors first reported a position in VRTX in Q2 2020 and has held it in 25 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Prudent Man Advisors held 3,827 shares of Vertex Pharmaceuticals worth $1.9M as of Q2 2026.
  • Prudent Man Advisors bought 400 Vertex Pharmaceuticals shares in Q2 2026, an estimated $177K.
  • Vertex Pharmaceuticals made up 0.43% of Prudent Man Advisors's portfolio in Q2 2026, its #61 holding.
  • Prudent Man Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Prudent Man Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.